1 / 8

Overview of Pharmaceutical Coverage and Spending in Mexico

This overview highlights the pharmaceutical landscape in Mexico, focusing on the partial coverage through health insurance schemes and the dominance of public provision by generics. It categorizes the market into innovative medicines, interchangeable generics, and similares. With a high volume of medicines sold via private pharmacies due to limited public insurance coverage, private financing significantly outweighs public financing. Although there has been growth in pharmaceutical spending, it remains among the lowest per capita in OECD countries, with projections indicating continued incremental increases in sales.

kaida
Télécharger la présentation

Overview of Pharmaceutical Coverage and Spending in Mexico

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceutical Overview

  2. Pharmaceutical Overview (1) • Pharmaceuticals partially covered through various health insurance schemes • Public insurance provision dominated by generics • Traditionally, three main classes of medicines in the market: • Innovative (patented); • “Interchangeable generics” (approved and registered by MoH based on bioequivalence tests); and • “Similar generics” or similares (generics approved and registered without bioequivalence tests) • Public insurance provision of similaresphased out 2005-present

  3. Pharmaceutical Overview (2) • High volume of medicines sold through private pharmacies due to insufficient public health insurance coverage of pharmaceuticals • Private financing of medicines far outweighs public financing: 80% vs. 20% • Majority of private spending on medicines is OOP (over 95%) • Still, overall, lowest consumption of pharmaceutical products per capita in OECD

  4. Snapshot of Pharmaceutical Spending • Pharmaceutical spending as % TEH 2nd highest in OECD (27.1% in 2009) • Per capita spending 2nd lowest in OECD (2009) • Medium growth in per capita pharmaceutical spending in 2000s, from very low rates at beginning of decade • Between 1999-2009 per capita spending almost tripled from USD 87.3 to USD 249.9 (PPP) • Incremental growth expected: pharmaceutical sales projected to rise from US$13 billion (MXN161 billion) in 2011 to US$18 billion in 2015

  5. Total Expenditure on Pharmaceuticals and Other Medical Non-durables, % TEH, Mexico, 1999-2009 Source: OECD Stat (2012)

  6. Total Expenditure on Pharmaceuticals, % of TEH, 1999-2009, Mexico and Select OECD Countries Source: OECD Stat (2012)

  7. Total Per Capita Spending, Pharmaceuticals and Other Medical Non-durables, US$ PPP, Mexico, 1999-2009 Source: OECD Stat (2012)

  8. Total Per Capita Spending, Pharmaceuticals and Other Medical non-durables, US$ PPP, 2010 or Closest Year, OECD Source: OECD Stat (2012)

More Related